ISLB 2020Nov 12, 2020
The Epic Sciences team presented at the virtual ISLB 2020 Annual Congress Meeting – October 30, 2020.
CTC + ctDNA: Accelerating Clinical Drug Development
About this presentation:
Epic Sciences and Predicine have entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine’s ctDNA-based testing and Epic’s CTC-based testing. Predicine’s lead offering is PredicineATLAS, the broadest CLIA-certified ctDNA-based assay that analyzes 600 cancer-related genes, using next generation sequencing. Epic’s CTC-based platform offers testing of AR-V7, AR-N term, PSMA, ER, PR and other phenotypic tests. The combination of both approaches allows pharmaceutical partners engaged in clinical trials to measure both genotypic and phenotypic markers from a single blood draw.
Download the presentation slides or watch presentation with narration
Shidong Jia, MD, PhD
Founder & CEO
Richard Wenstrup, MD
Chief Medical Officer